For instance, a person with
aortic valve replacement at age 39 might be denied life insurance.
Researchers analyzed records of 196 adult patients who underwent transcatheter
aortic valve replacement at Ronald Reagan UCLA Medical Center between August 2012 and June 2016.
Not exact matches
The more frequently a hospital performs a minimally invasive technique called transcatheter
aortic valve replacement, or TAVR, to replace a damaged
aortic heart
valve, the better patients fare, on average, immediately after the procedure, researchers reported
at the American College of Cardiology's 65th Annual Scientific Session.
The introduction of minimally invasive transcatheter
aortic valve replacement (TAVR) for treatment of
aortic stenos not only has increased the number of patients eligible for
aortic valve replacement (AVR), but also has led to a decrease in patient mortality, according to a study released today
at the 50th Annual Meeting of The Society of Thoracic Surgeons.
The FDA approved the CoreValve System to treat patients with severe
aortic stenosis who are
at high risk for surgery based on groundbreaking research showing the transcatheter heart
valve had superior survival rates
at one year when compared to open - heart surgery, the current gold standard for
aortic valve replacement.
Transcatheter
aortic valve replacement with a self - expanding
valve prosthesis for the first time has demonstrated significantly lower death rates
at one year compared with conventional surgical
valve replacement in high - risk patients with severe
aortic stenosis, according to research presented
at the American College of Cardiology's 63rd Annual Scientific Session.
Strong results from the other arm of CoreValve's U.S. Pivotal Trial with patients
at extreme risk for standard
aortic valve -
replacement surgery were reported in October and led to Food and Drug Administration approval for the device in this population.